Efficacy and safety of fractional microablative radiofrequency versus topical estriol in treating genitourinary syndrome of menopause: A pilot study
International Journal of Gynecology & Obstetrics · 2026-04 · 173 (1) · 521-524
DOI: 10.1002/ijgo.70563 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 09.10.2025. Verfasst von Priscila de Almeida Torre und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Federal Fluminense University (UFF), Rio de Janeiro, RJ, Brazil. Hauptthemen laut MEDLINE: Estriol, Female Urogenital Diseases, Menopause. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To compare the efficacy and safety of fractional microablative radiofrequency (RF) and topical estriol in the treatment of genitourinary syndrome of menopause (GSM).
Methods
This pilot randomized controlled trial included 30 healthy postmenopausal women with GSM. Participants were randomly assigned to receive either fractional microablative RF plus placebo cream (RF group) or topical estriol plus sham RF (estriol group). Both treatments were administered over 3 months. Primary outcomes included vaginal health (Vaginal Health Index Score—VHIS), sexual function (Female Sexual Function Index—FSFI), and urinary symptoms (International Consultation on Incontinence Questionnaire—Short Form—ICIQ‐SF). Safety was assessed through reports of adverse effects.
Results
Both RF and estriol significantly improved VHIS, FSFI, and ICIQ‐SF scores ( p < 0.05). Estriol provided greater improvement in sexual desire, while RF demonstrated superior results in satisfaction, dyspareunia reduction, and epithelial elasticity. No severe adverse effects occurred; mild discomfort was reported in the RF group.
Conclusion
Fractional microablative RF and topical estriol are both effective and safe for relieving GSM symptoms. RF offers a promising non‐hormonal alternative, especially for women who cannot or choose not to use estrogen therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Federal Fluminense University (UFF), Rio de Janeiro, RJ, Brazil.
- Health Sciences Center, Federal University of Rio Grande do Norte (UFRN), Natal, RN, Brazil.
ORCID-Profile: Priscila de Almeida Torre, Susana Cristina Aidé Viviani Fialho, Ana K Gonçalves
Zitieren
APA
Torre, P. A., Fialho, S. C. A. V., do Val Guimarães, I. C. C., Zunino, A. X., Castro, T., Martins, C. A. O., & Gonçalves, A. K. (2026). Efficacy and safety of fractional microablative radiofrequency versus topical estriol in treating genitourinary syndrome of menopause: A pilot study. International Journal of Gynecology & Obstetrics, 173(1), 521-524. https://doi.org/10.1002/ijgo.70563
Vancouver
Torre PA, Fialho SCAV, do Val Guimarães ICC, Zunino AX, Castro T, Martins CAO, et al. Efficacy and safety of fractional microablative radiofrequency versus topical estriol in treating genitourinary syndrome of menopause: A pilot study. International Journal of Gynecology & Obstetrics. 2026;173(1):521-524. doi:10.1002/ijgo.70563
BibTeX
@article{Torre2026,
author = {Torre, Priscila de Almeida and Fialho, Susana Cristina Aidé Viviani and do Val Guimarães, Isabel Cristina Chulvis and Zunino, Ana Ximena and Castro, Tuani and Martins, Caroline Alves de Oliveira and Gonçalves, Ana K},
title = {Efficacy and safety of fractional microablative radiofrequency versus topical estriol in treating genitourinary syndrome of menopause: A pilot study},
journal = {International Journal of Gynecology & Obstetrics},
year = {2026},
volume = {173},
number = {1},
pages = {521--524},
doi = {10.1002/ijgo.70563}
}
EUVIMED